Cardiogen for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Cardiogen for Health & Longevity

Created on 09/01/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

Cardiogen is a four-amino-acid compound designed to act on heart tissue and sold as a laboratory chemical rather than as a medicine. Its supporting record is small, one-sided, and comes almost entirely from the institute that created it. None of it involves people. The most concrete documented harms belong to the unlicensed supply channel rather than the molecule. (Full Review)

Protocol

Standard circulating protocol
10 mg subcutaneously every 3 to 7 days
Run as a 2 to 4 week cycle. No trial supports this dose, frequency or duration.
Intensive variant
20 mg subcutaneously, same 3 to 7 day interval
Sometimes extended weekly to 16 weeks. The step from 10 to 20 mg is arbitrary rather than dose-ranging.
Competing oral approach
Oral capsule courses of 10 to 30 days
Repeated two or three times yearly. Bioavailability is unmeasured either way.
Time to effect
Time to effect
Unknown
No human outcome has ever been measured. Circulating expectations of cellular change by weeks 2 to 4 are extrapolated from cell-culture timescales of 24 to 72 hours, not from anything observed in people.
Half-life and its consequence
Cleaved within minutes
Intermittent large doses produce brief spikes rather than sustained exposure. No measured half-life has been published.

Benefits

Contraindications
  • Active malignancy, or any cancer treated within the past 5 years
  • Pregnancy and lactation
  • Age under 18
  • Active infection or febrile illness
  • Bleeding disorders such as haemophilia, platelet count below 50 × 109/L, or anticoagulation with international normalised ratio above 3.5
  • Decompensated heart failure, New York Heart Association Class III-IV, or myocardial infarction within 90 days
  • Severe liver impairment, Child-Pugh Class C, or advanced kidney disease with estimated glomerular filtration rate below 30 mL/min/1.73 m²
  • Known hypersensitivity to any peptide preparation, or to benzyl alcohol
    •
Key Interactions
  • Anticoagulants and antiplatelet agents, which reduce clotting (warfarin, apixaban, clopidogrel, low-dose aspirin)
  • Over-the-counter analgesics (ibuprofen, naproxen, aspirin)
  • Over-the-counter antihistamines (cetirizine, loratadine, diphenhydramine)
  • Prescribed cardiovascular therapy (beta blockers such as metoprolol; angiotensin-converting enzyme inhibitors such as lisinopril)
  • Other peptide bioregulators (Epitalon, Pinealon, Vesugen, Cartalax)
  • Supplements with additive cardiac effects (coenzyme Q10, taurine, L-Carnitine, D-Ribose)
  • Supplements with additive bleeding effects (fish oil, nattokinase, garlic extract, high-dose vitamin E, Ginkgo biloba)
  • Concurrent interventions (new resistance or endurance training blocks, sauna protocols, cardiac rehabilitation)
    •

Risk & Side Effects

  • Low: Immune reactions to synthesis by-products; endotoxin exposure from unregulated vials; dose and identity error from mislabelled product; injection-site infection and local reactions
    •
  • Speculative: Weakening of a tumour-suppressor pathway; action on tumour blood supply; pro-fibrotic drift in cardiac fibroblasts; off-target binding to histones and DNA; uncharacterised reproductive and genotoxic effects
    •

Monitoring

Marker Target Why
High-sensitivity C-reactive protein Below 0.5 mg/L Tracks the cell-ageing inflammation the peptide targets, and rises with contamination reactions
Interleukin-6 Below 1.5 pg/mL Second inflammatory signal, less affected by acute infection
N-terminal pro-B-type natriuretic peptide Below 50 pg/mL under age 65 Reflects heart wall stretch, the closest routine proxy for the claimed cardiac benefit
High-sensitivity cardiac troponin T Below 5 ng/L Detects ongoing myocardial injury and any new insult during a course
Apolipoprotein B Below 80 mg/dL Carries the actual artery-narrowing burden that no peptide claim addresses
Estimated glomerular filtration rate Above 90 mL/min/1.73 m² Clearance capacity for injected impurities and diluent
Alanine aminotransferase Below 25 U/L in men, below 20 U/L in women Organ safety screen for any unapproved injected compound
Absolute eosinophil count Below 200 cells/µL Early signal of hypersensitivity to synthesis by-products
Seated blood pressure 110-120 / 70-75 mmHg Cheapest cardiovascular endpoint available and a check on unexpected circulatory change
Resting heart rate 50-65 bpm Sensitive to inflammatory and febrile reactions before symptoms appear

Cadence: Baseline before a first course, repeat at 4 weeks, at the end of a course, then every 6 to 12 months, with an unscheduled panel after any febrile or injection-site reaction.

Qualitative Assessment

  • Exercise tolerance at a fixed workload, such as heart rate at a set pace or wattage
  • Breathlessness on exertion and any change in usual exercise capacity
  • Palpitations, chest discomfort or new exercise intolerance, each of which warrants stopping
  • Injection-site appearance over 48 hours: redness, hardening, bruising, warmth
  • Fever, shaking chills or flu-like malaise within 12 hours of a dose
  • Sleep quality and daytime energy, recorded daily
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.